...
首页> 外文期刊>Journal of cardiac failure >Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy
【24h】

Serum Matrix Metalloproteinases as Quantitative Biomarkers for Myocardial Fibrosis and Sudden Cardiac Death Risk Stratification in Patients With Hypertrophic Cardiomyopathy

机译:血清基质金属蛋白酶作为肥厚型心肌病患者心肌纤维化和心脏猝死危险分层的定量生物标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Hypertrophic cardiomyopathy (HCM) is associated with an increased risk of sudden cardiac death due to ventricular tachycardia (VT), and myocardial fibrosis reflects an important risk factor. Several matrix metalloproteinases (MMPs) and procollagen N-terminal propeptides (PNPs) are involved in collagen turnover and discussed as fibrosis biomarkers. We aimed to identify biomarkers that correlate with myocardial fibrosis in late-gadolinium-enhancement cardiac magnetic resonance imaging (LGE-CMR) and/or cardiac events (syncope, VT) in HCM patients.
机译:背景:肥厚型心肌病(HCM)与因室性心动过速(VT)导致的心脏猝死的风险增加有关,心肌纤维化反映出重要的危险因素。几种基质金属蛋白酶(MMPs)和胶原蛋白N末端前肽(PNPs)参与胶原蛋白更新,并被讨论为纤维化生物标志物。我们旨在鉴定与HCM患者晚期late增强心脏磁共振成像(LGE-CMR)和/或心脏事件(晕厥,VT)中的心肌纤维化相关的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号